10.01.03
Indication: Type 2 diabetes
Source: International Diabetes Federation (IDF) Congress, Paris, France, August 2003
Research: A double-blind, placebo-controlled study was conducted on 52 subjects, which were randomly assigned to receive either a placebo, 500 mcg or 1000 mcg of chromium, as chromium picolinate, per day. All 52 subjects had elevated glycosylated hemoglobin (HbA1c) levels greater than 8%, despite insulin requirements of ≥ 50 units per day. (HbA1c is a marker of long-term blood sugar control). Investigators also measured serum lipids, body mass index (BMI), blood pressure and insulin requirements.
Results: Significant improvements were found in the cholesterol/HDL ratio (-0.46 and –0.32 in the 500 mcg and 1000 mcg chromium groups, respectively). Trends for improvements were found for triglyceride levels in both chromium groups. Other endpoints were not significantly different between all three groups at the end of the study. This was the fourth study using 1000 mcg of chromium that showed significant effects in improving blood sugar levels in people with insulin resistance and diabetes. There are two large definitive clinical trials now underway in the U.S. to further evaluate the effects of 1000 mcg of chromium (as Chromax” chromium picolinate) on blood sugar levels in people with type 2 diabetes or metabolic syndrome.
Source: International Diabetes Federation (IDF) Congress, Paris, France, August 2003
Research: A double-blind, placebo-controlled study was conducted on 52 subjects, which were randomly assigned to receive either a placebo, 500 mcg or 1000 mcg of chromium, as chromium picolinate, per day. All 52 subjects had elevated glycosylated hemoglobin (HbA1c) levels greater than 8%, despite insulin requirements of ≥ 50 units per day. (HbA1c is a marker of long-term blood sugar control). Investigators also measured serum lipids, body mass index (BMI), blood pressure and insulin requirements.
Results: Significant improvements were found in the cholesterol/HDL ratio (-0.46 and –0.32 in the 500 mcg and 1000 mcg chromium groups, respectively). Trends for improvements were found for triglyceride levels in both chromium groups. Other endpoints were not significantly different between all three groups at the end of the study. This was the fourth study using 1000 mcg of chromium that showed significant effects in improving blood sugar levels in people with insulin resistance and diabetes. There are two large definitive clinical trials now underway in the U.S. to further evaluate the effects of 1000 mcg of chromium (as Chromax” chromium picolinate) on blood sugar levels in people with type 2 diabetes or metabolic syndrome.